Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5097168 | 0.98 | KDM4E (0.57) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL7238703 | 0.86 | MEN1 (0.61) | KDM4EPOLBALDH1A1HPGDCA2 | |
| SCHEMBL14176213 | 0.84 | KDM4E (0.57) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL20455530 | 0.84 | MEN1 (0.60) | KDM4EPOLBALDH1A1HPGDCA2 | |
| Hydrochloric Acid SCHEMBL6625763 | 0.84 | MEN1 (0.60) | KDM4EPOLBALDH1A1HPGDCA2 | |
| SCHEMBL382822 | 0.81 | KDM4E (0.66) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL6339834 | 0.80 | KDM4E (0.56) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL267307 | 0.80 | KDM4E (0.62) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL22345013 | 0.79 | KDM4E (0.80) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL30009450 | 0.79 | KDM4E (0.80) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230358732-A1 | METHODS AND COMPOUNDS FOR DETECTION AND BINDING OF ALDEHYDES | UNIVERSITY OF OTTAWA (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230358732-A1 | METHODS AND COMPOUNDS FOR DETECTION AND BINDING OF ALDEHYDES | UNIVERSITY OF OTTAWA (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11696960-B2 | Methods and compounds for detection and binding of aldehydes | UNIVERSITY OF OTTAWA (CA) | 2023-07-11 | — | — | US | disclosed |
| US-11696960-B2 | Methods and compounds for detection and binding of aldehydes | UNIVERSITY OF OTTAWA (CA) | 2023-07-11 | — | — | US | disclosed |
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1812403-A2 | PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006047528-A2 | PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089496-A1 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230358732-A1 | METHODS AND COMPOUNDS FOR DETECTION AND BINDING OF ALDEHYDES | ALDH16A1, CRAT, ALDH1A1 | KDM4E 4134/4885CYP1A2 926/4885CYP2C19 1333/4885 |
| US-11696960-B2 | Methods and compounds for detection and binding of aldehydes | ALDH2, ALDH16A1, ALDH1B1 | KDM4E 3091/4885CYP1A2 1057/4885CYP2C19 1616/4885 |
| US-20060089496-A1 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | F12, TFPI, PRSS1 | KDM4E 3453/4885CYP1A2 556/4885CYP2C19 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.